References
1. Okamoto, T., Nagaya, K., Sugiyama, T., Aoyama, A., Nii, M., & Azuma, H. (2021). Two patients of trisomy 21 with transient abnormal myelopoiesis with hypereosinophilia without blasts in peripheral blood smears. Pediatric hematology and oncology , 38 (2), 168–173. https://doi.org/10.1080/08880018.2020.1826070
2. Yamato, G., Park, M. J., Sotomatsu, M., Kaburagi, T., Maruyama, K., Kobayashi, T., Nishi, A., Sameshima, K., Ohki, K., & Hayashi, Y. (2021). Clinical features of 35 Down syndrome patients with transient abnormal myelopoiesis at a single institution. International journal of hematology , 113 (5), 662–667. https://doi.org/10.1007/s12185-020-03066-7
3. Manohar, S., & Jayakumar, N. (2022). ”TAM”ing of the shrew-challenges in the diagnosis of Neonatal leukemia with Down’s syndrome -A case report with literature review. Indian journal of pathology & microbiology , 65 (3), 699–701. https://doi.org/10.4103/ijpm.ijpm_731_21
4. Al-Kershi, S., Golnik, R., Flasinski, M., Waack, K., Rasche, M., Creutzig, U., Dworzak, M., Reinhardt, D., & Klusmann, J. H. (2021). Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS). Empfehlungen für die Diagnose und Behandlung von Kindern mit transienter abnormer Myelopoese (TAM) und myeloischer Leukämie bei Down Syndrom (ML-DS). Klinische Padiatrie , 233 (6), 267–277. https://doi.org/10.1055/a-1532-2016
5. Hayasaka, I., Cho, K., Morioka, K., Kaneshi, Y., Akimoto, T., Furuse, Y., Moriichi, A., Iguchi, A., Cho, Y., Minakami, H., & Ariga, T. (2015). Exchange transfusion in patients with Down syndrome and severe transient leukemia. Pediatrics international: official journal of the Japan Pediatric Society , 57 (4), 620–625. https://doi.org/10.1111/ped.12586
6. Park, E. S., Kim, S. Y., Yeom, J. S., Lim, J. Y., Park, C. H., & Youn, H. S. (2008). Extreme thrombocytosis associated with transient myeloproliferative disorder with Down Syndrome with t(11;17)(q13;q21).Pediatric blood & cancer , 50 (3), 643–644. https://doi.org/10.1002/pbc.21029
7. Kosmidou, A., Tragiannidis, A., & Gavriilaki, E. (2023). Myeloid Leukemia of Down Syndrome. Cancers , 15 (13), 3265. https://doi.org/10.3390/cancers15133265
8. Yuzawa, K., Terui, K., Toki, T., Kanezaki, R., Kobayashi, A., Sato, T., Kamio, T., Kudo, K., Sasaki, S., Endo, M., Ozono, S., Nomura, K., & Ito, E. (2020). Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21. Pediatric blood & cancer , 67 (4), e28188. https://doi.org/10.1002/pbc.28188
9. Grimm, J., Heckl, D., & Klusmann, J. H. (2021). Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome. Frontiers in oncology , 11 , 636633. https://doi.org/10.3389/fonc.2021.636633
10. Bhatnagar, N., Nizery, L., Tunstall, O. et al. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr Hematol Malig Rep 11 , 333–341 (2016). https://doi-org.evms.idm.oclc.org/10.1007/s11899-016-0338-x
11. Crispino, J. D., & Horwitz, M. S. (2017). GATA factor mutations in hematologic disease. Blood , 129 (15), 2103–2110. https://doi.org/10.1182/blood-2016-09-687889
12. Massey, G. V., Zipursky, A., Chang, M. N., Doyle, J. J., Nasim, S., Taub, J. W., Ravindranath, Y., Dahl, G., Weinstein, H. J., & Children’s Oncology Group (COG) (2006). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood ,107 (12), 4606–4613. https://doi.org/10.1182/blood-2005-06-2448
13. Walter, R.B., Appelbaum, F.R. & Estey, E.H. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. Leukemia 35, 295–298 (2021). https://doi-org.evms.idm.oclc.org/10.1038/s41375-020-01110-3
14. Lee, J. W., Kim, S., Jang, P. S., Chung, N. G., Cho, B., & Kim, M. (2021). Marked thrombocytosis resulting in pseudohyperkalemia in a neonate with transient abnormal myelopoiesis. Pediatric blood & cancer , 68 (8), e28986. https://doi.org/10.1002/pbc.28986